Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted

Executive Summary

The latest regulatory news on new versions of complex products and delivery systems from our FDA Performance Tracker.

Advertisement

Related Content

Taking Biosimilars Down A PEG: Why Copying Neulasta Isn’t So Easy
Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA
Hikma's CRL Proves GSK's Witty Was Right: Generic Advair Is Hard
Advair Generic: Mylan Takes Issue With US FDA's 'Major' Concerns
Advair Generic Approval Uncertain Despite US FDA Denial Of Sandoz Petition
Biosimilars: Sandoz Pegfilgrastim Review, Amgen Adalimumab Launch Extended To 2018
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Keeping Track: KemPharm Apadaz Delay; Cholera Vaccine Approved
Keeping Track: Gilead Aims To Expand TAF To HBV; BioMarin's Kyndrisa Get Complete Reponse
Managing The World’s First Blockbuster Generic: An Interview With Sandoz’s George

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel